[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gilead Sciences Inc (GILD)

Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Gilead Sciences Inc 333 LAKESIDE DRIVE FOSTER CITY CA 94404 USA

www.gilead.com Employees: 17,000 P: 650-574-3000

Sector:

Medical

Description:

Gilead Sciences is a pioneer in developing drugs for the treatment of human immunodeficiency virus, liver diseases, hematology/oncology diseases and inflammation/respiratory diseases. The company has a strong HIV franchise with key HIV/AIDS therapies like tenofovir alafenamide based products - Genvoya, Odefsey, Descovy, Biktarvy and Truvada. The portfolio also includes hepatitis C virus drugs like Harvoni and Epclusa and HBV drug. The first cell therapy approved for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, has diversified Gilead's portfolio. Tecartus, another CAR T-cell therapy, was granted an accelerated approval in the United States for the treatment of relapsed or refractory mantle cell lymphoma. The company is also working on diversifying and growing its business beyond antivirals into other therapeutic areas. Gilead is also making inroads in the oncology space with strategic collaborations and acquisitions.

Key Statistics

Overview:

Market Capitalization, $K 172,254,544
Enterprise Value, $K 189,626,544
Shares Outstanding, K 1,239,955
Float, K 1,236,235
% Float 99.70%
Short Interest, K 24,386
Short Float 1.97%
Days to Cover 3.86
Short Volume Ratio 0.45
% of Insider Shareholders 0.30%
% of Institutional Shareholders 83.67%

Financials:

Annual Sales, $ 29,443 M
Annual Net Income, $ 8,510 M
Last Quarter Sales, $ 7,803 M
Last Quarter Net Income, $ -10,496 M
EBIT, $ -2,498 M
EBITDA, $ 262,000 K

Growth:

1-Year Return 21.57%
3-Year Return 86.63%
5-Year Return 101.23%
5-Year Revenue Growth 19.26%
5-Year Earnings Growth 14.95%
5-Year Dividend Growth 16.18%

Per-Share Information:

Most Recent Earnings -6.75 on 08/04/26
Next Earnings Date 10/29/26
Earnings Per Share ttm -0.39
EPS Growth vs. Prev Qtr -432.51%
EPS Growth vs. Prev Year -435.82%
Annual Dividend & Yield (Paid) 3.22 (2.32%)
Annual Dividend & Yield (Fwd) 3.28 (2.37%)
Most Recent Dividend 0.820 on 06/15/26
Next Ex-Dividends Date 09/15/26
Dividend Payable Date 09/29/26
Dividend Payout Ratio 953.76%
Most Recent Split 2-1 on 01/28/13

GILD Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -2.11%
Return-on-Assets % -0.75%
Profit Margin % 28.90%
Debt/Equity 2.23
Price/Sales 5.83
Price/Cash Flow 13.22
Price/Book 14.63
Book Value/Share 9.46
Interest Coverage 10.57
60-Month Beta 0.32

GILD Dividends

Date Value
06/15/26 $0.8200
03/13/26 $0.8200
12/15/25 $0.7900
09/15/25 $0.7900
06/13/25 $0.7900
03/14/25 $0.7900
12/13/24 $0.7700
09/13/24 $0.7700
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.